CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib

• Josephine M. Vos,
• Nickolas Tsakmaklis,
• Christopher J. Patterson,
• Kirsten Meid,
• Jorge J. Castillo,
• Philip Brodsky,
• Tomas Ganz,
• Steven T. Pals,
• Marie José Kersten,
• Lian Xu,
• Guang Yang,
• Steven P. Treon,
• Zachary R. Hunter

Affiliations

Josephine M. Vos

St. Antonius Hospital, Nieuwegein, The Netherlands;Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA

Nickolas Tsakmaklis

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA

Christopher J. Patterson

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA

Kirsten Meid

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA

Jorge J. Castillo

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA;Department of Medicine, Harvard Medical School, Boston, MA, USA

Philip Brodsky

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA

Tomas Ganz

David Geffen School of Medicine, Los Angeles, CA, USA

Steven T. Pals

Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands

Marie José Kersten

Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands

Lian Xu

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA

Guang Yang

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA;Department of Medicine, Harvard Medical School, Boston, MA, USA

Steven P. Treon

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA;Department of Medicine, Harvard Medical School, Boston, MA, USA

Zachary R. Hunter

Bing Center for WM, Dana Farber Cancer Insitute, Boston, MA, USA;Department of Medicine, Harvard Medical School, Boston, MA, USA